Clinical analysis and drug resistance monitoring of multidrug-resistant organism infection in Leshan region
CHEN Ke-fan1, YANG Jian-ke1, ZHANG Mei2, FAN Hong3, YUAN Shu-sheng1
1. The People’s Hospital of Leshan, Leshan, Sichuan 614000, China; 2. Armed Police Corps Hospital of Sichuan Province, Leshan, Sichuan 614000, China; 3. Leshan Hospital of Traditional Chinese Medicine, Leshan, Sichuan 614000, China
Abstract：Objective To investigate the infection status and drug resistance of multidrug-resistant organism (MDRO) in Leshan region. Methods Drug-resistant bacteria isolated from all kinds of specimens from patients in three tertiary grade Ahospitals in Leshan city from January 2017 to December 2018 were selected as the research subjects. Bacterial identification and drug sensitivity test were conducted, and the source, clinical distribution and drug resistance characteristics of MDRO were analyzed. Results A total of 13,287 non-repetitive strains were isolated from three tertiary grade A hospitals in Leshan city from January 2017 to December 2018, including 3,257 strains of MDRO (accounting for 24.51%). The detected strains of MDRO were mainly extended-spectrum β-lactamases (ESBLs)-producing Escherichia coli, ESBLs-producing Klebsilla pneunmoniae and multi-drug resistance Acinetobacter baumannii (MDR-Ab). The main sources of MDRO specimens were sputum (44.67%) and urine (19.25%). The clinical source of MDRO specimens was mainly from intensive care unit (19.19%), followed by neonatology department (15.23%) and neurosurgery department (14.15%). ESBLs-producing Escherichia coli and ESBLs-producing Klebsilla pneunmoniae were sensitive to meropenem and imipenem, MDR-AB to ampicillin/sulbactam,multi-drug resistant/pan-drug resistant Pseudomonas aeruginosa (MDR-PA /PDR-PA) only to levofloxacin, carbapenem-resistant Klebsiella pneumonia totigecycline, and methicillin-resistant Staphylococcus aureus (MRSA) to vancomycin and tigecyclin. Conclusions ESBLs-producingEscherichia coli is the most common multidrug-resistant bacterium in Leshan region, followed by ESBLs-producing Klebsilla pneunmoniae and MDR-AB. As for clinical treatment, antibiotics should be reasonably used in combination with drug sensitivity results of MDRO, drug indications should be strictly controlled, and preventive measures should be taken simultaneously and actively so as reduce the outbreak of nosocomial infection.
2020, Vol. 27 
